M Stanley Cuts JD HEALTH TP to HKD45, Maintains Equalweight Rating

LongbridgeAII'm LongbridgeAI. Here is the key information I extracted
- Morgan Stanley updated its model for JD HEALTH and lowered its EPS forecasts for 2026 to 2028 by 1% to 9% while cutting the target price to HKD 45 with an Equalweight rating.
- The adjustments reflect slower nutritional supplement growth, reduced margin assumptions, intensifying e-commerce competition, and a slowdown in organic growth.…
Disclaimer

Morgan Stanley issued a research report stating that after updating its model following JD HEALTH (06618.HK) -2.440 (-6.999%) Short selling $304.93M; Ratio 32.620% 's third-quarter results, it lowered its EPS forecasts for 2026 to 2028 by 1%, 2% and 9%, respectively, reflecting slower growth in nutritional supplements and corresponding reductions in margin assumptions. The broker rolled forward its DCF model to start from 2027 and cut the TP from HKD49.6 to HKD45, while maintaining an "Equalweight" rating.

The broker said JD HEALTH (06618.HK) -2.440 (-6.999%) Short selling $304.93M; Ratio 32.620% is China's leading healthcare e-commerce platform by direct sales scale and is expected to benefit in the long run from the online expansion potential of healthcare products, particularly pharmaceuticals. The company also receives support from its parent company in traffic guidance, platform business revenue sharing and logistics. However, accelerating slowdown in organic growth, softer macro conditions, intensifying competition among e-commerce peers and other disruptive internet healthcare models continue to pose pressure. Short-term margin growth is also slowing due to upfront investments in new businesses.

Under its base-case scenario, the broker assumes revenue CAGR of about 10% for 2026 to 2028, with margins remaining broadly stable.(da/u)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-11-19 16:25.)

Source: AASTOCKS News The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.